Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Novo Nordisk A/STrade
Vanguard International High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Vanguard International High Dividend Yield ETF — how do they compare? Novo Nordisk A/S trades at $46.28 (market cap $207.85B), while Vanguard International High Dividend Yield ETF trades at $104.49. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

NVOVYMI
Market Cap
$207.85B
Sector
HealthBroad Market / Factor
52-Week High
$63.98$105.05
52-Week Low
$35.29$82.92
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Vanguard International High Dividend Yield ETF

VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.48, down slightly by 0.11% today. The technical outlook is bullish based on moving averages, with key support at $104 and resistance at $105. Recent news highlights strong institutional buying and its appeal to retirees seeking international dividend income, with the fund outperforming the S&P 500 over the past five years.

The ETF offers a compelling income play with a 3.4% dividend yield and an 8.86% five-year dividend CAGR, supported by bullish analyst sentiment. Risks include currency fluctuations from international exposure and broader market volatility, but its diversification and high yield provide a defensive stance amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Vanguard International High Dividend Yield ETF

VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.

Read more on VYMI